Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propranolol versus bevacizumab for treatment-resistant diabetic macular edema
IRCT20260710070114N1Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Aug 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetic macular edema (DME) comparing Intravitreal propranolol with Intravitreal bevacizumab (2 arms). Primary endpoints: Change in retinal thickness, Change in best-corrected visual acuity and 2 more. Started Aug 2026; status: completed.
02
Drugs
propranololbevacizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on IRCT20260710070114N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260710070114N1.